Le Lézard
Classified in: Health
Subject: FDA

StimGuide by Magstim: The First Clinical TMS Navigation System to Receive 510K Clearance


EDEN PRAIRIE, Minnesota, May 16, 2019 /PRNewswire/ -- Magstim®TMS has launched the very first Transcranial Magnetic Stimulation navigation system specifically developed for the clinical market.

The Magstim StimGuide® 3D navigation system aligns four distinct parameters to guide clinicians to a precise target area for TMS treatment.

StimGuide®, which has received FDA 510K clearance, is a unique navigation system used with Magstim's Horizon® Performance TMS Therapy System. It provides precise and consistent coil positioning in the treatment of Major Depressive Disorder.

The 3D navigation system aligns four distinct parameters to guide clinicians to a precise target area for treatment, reducing any potential variability in treatment and improving confidence and consistency in the delivery of the TMS therapy.   

Dr Mark George, MD from Medical University of South Carolina, said: "I am thrilled that this technology is now available. As the TMS research field continues to advance towards treating targets tailored for each patient, a tool like StimGuide® provides a solution for simple, repeatable, and precise coil positioning."

StimGuide was developed to provide a solution for the majority of clinical centers that do not have access or the resources to provide pre-treatment MRIs for patients. It offers the benefits of 3D navigation  without the expense and complexity associated with more complicated navigation technology.

With this new solution, clinicians do not have to choose between a one-dimensional contact sensor or a more complex research-based navigation option. With StimGuide®, they have a solution that leapfrogs a cap and measuring method or contact sensor technology and provides the benefits of precise and repeatable coil positioning.

As the TMS field continues to grow and evolve in the treatment of Major Depressive Disorder, there is an increasing need for a tool that provides a quality control tool that reduces treatment variability among technicians and within a treatment session.

"I am convinced that StimGuide® will improve patient care because it ensures reliable placement over the intended treatment target providing confidence to experienced and new TMS treaters.  StimGuide® accurately measures the distance of the coil from the intended target as well as rotation and pitch ensuring every pulse train is delivered in the optimal coil position," said Lothar Krinke, Group CEO, Magstim®

Several centers across the US are already using the StimGuide® technology as part of a Magstim-sponsored clinical study which measures the quality of TMS pulses delivered during a treatment session. The CONFIDENT study aims to quantify the percentage of pulses that are delivered within four distinct parameters used for positioning.

Dr Roger Pottanat, MD from Weymouth, MA, represents one of the sites in the CONFIDENT study. He said, "StimGuide improves our confidence that we are treating the right location regardless of changes in patient positioning."

StimGuide® operates with Magstim's Horizon® Performance System which recently received 510K for the iTBS 3-minute protocol (theta burst). The combined solution features the proprietary Energy Recovery System (ERS) that ensures consistent treatment throughout a session with no pulse decay. The versatile E-z Cool Coil has a longer pulse width that is optimized for patient comfort and has been shown to be more tolerable for patients.

Magstim pioneered TMS therapy 30 years ago and it is now widely used to treat Major Depressive Disorder across Europe, the US and the rest of the world.

Please direct media enquiries to Jo Wallace at Yogi on +44 (0) 2920 460 234 or [email protected].

SOURCE Magstim


These press releases may also interest you

at 10:38
Future Health, a leading innovator in healthcare solutions, and the innovative force behind Done, a platform that allows users to manage their ADHD, today announced its initiative aimed at alleviating clinician burnout. Its Psychiatric Collaborative...

at 10:37
Pvolve, the fitness franchise that pairs low-impact, functional movement with resistance equipment to build strong, mobile bodies, announced the largest franchise deal in the company's history. The agreement is for five studio locations across...

at 10:36
Once Upon a Coconut, a leading provider of premium coconut water, is pleased to announce the appointment of Gary Brecka as the new Chair of its Health and Wellness Board. With his extensive experience in the industry and commitment to promoting...

at 10:35
GE HealthCare today announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence (AI), advanced tools and an ergonomic design to speed exam time for clinicians while delivering a...

at 10:30
Hemodialysis and Peritoneal Dialysis Market in terms of revenue was estimated to be worth $92.0 billion in 2024 and is poised to reach $126.2 billion by 2029, growing at a CAGR of 6.5% from 2024 to 2029 according to a new report by...

at 10:20
Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains that closely mirror the one recently detected in cows,...



News published on and distributed by: